Multiplexed diagnostics are assays that are capable of analyzing multiple analytes in the single cycle of the assay procedure. These tools are evolved from diagnostic assays that screens single analyte in single run of the assay procedure and are used in research laboratories and diagnostics laboratories. Research and development laboratories use multiplexed assays in drug development procedure to screen multiple analytes. In diagnostics market, multiplexed assays are used in clinical laboratories and hospitals for the diagnosis of various diseases and disorders. Multiplexed assays are used for diagnosis of infectious diseases, cancer biomarkers, cardiac diseases, allergies and autoimmune diseases.
Request a Sample Copy of the Report @ http://www.mrrse.com/sample/1123
Multiplexed diagnostics techniques include very high density multiplexed assays, high density multiplexed assays, medium density multiplexed assays, low density multiplexed assays and next-generation sequencing. All the technologies used in multiplexing are based on the principle of screening of multiple analytes in single cycle of the assay. Very high density multiplexed assays include oligonucleotide arrays and phage display. High density multiplexed assays include bacterial artificial chromosome arrays and protein arrays. Medium density multiplexed assays include bead-based arrays, antibody assays, reverse assays and mass spectroscopy. Low density multiplexed assays include qPCR bead-based assays and microplate assays.
Inquiry on this report @ http://www.mrrse.com/enquiry/1123
Currently, medium density multiplexed assay market leads the overall multiplexed diagnostics market and is followed by low density multiplexed diagnostics assays. Bead-based arrays and antibody arrays is the most preferred multiplexed technique. Medium density arrays market is dominating the industry due to its multiple applications in other technologies used in the multiplexed diagnostics. For instance, bead-based assays used in combination with immunoassays and oligonucleotides in combination with protein assays. The cost of medium density multiplexed assays is lesser as compared to very high density and high density multiplexed assays thus resulting in added affordability and thereby growth in demand in emerging economies.
The global multiplexed diagnostics market is highly consolidated in nature. Bigger market players lead this market with their proprietary products and robust development strategies. Established players in the market follow the trend of large scale union and collaborative activities such as supply agreements, acquisitions and partnerships to expand their market share. Intensive competitive rivalry exists in the market as a result of price competition due to the presence of limited market players in the industry.
Read Complete Report with TOC @ http://www.mrrse.com/multiplexed-diagnostics-market
Geographically, North America is leading the global multiplexed diagnostics market. Highly developed healthcare infrastructure, developed technology and high rates of adoption are some of the major factors that are driving the growth of multiplexed diagnostics market in the North America. Asia-Pacific is the lucrative market for multiplexed diagnostics market owing to rapidly growing medical industry in the region. In addition, Asia-Pacific covers more than 50% of the global population and demonstrates the highest rates of morbidity of infectious diseases and cardiac diseases in this region. Japan is currently the most dominant market in the Asia-Pacific region and is followed by China and India. Government initiatives to create awareness about the available diagnostic procedures and research activities to boost the biotechnology industry in the respective countries will further augment the growth of multiplexed diagnostics market in emerging economies.
90 State Street,
Albany NY – 12207